ZAR2007: R-CHOP in Folicular Lymphoma Patients no Treated Previously. Consolidation With 90Y Ibritumomab Tiuxetan (Zevalin®) Versus Maintenance Treatment With Rituximab (MabThera®)

• Status: Completed
• Trial end date: 2017-10-30

Summary

After conventional induction treatment with R-CHOP (Rituximab, cyclophosphamide, adriamycin, vincristine and prednisone) the patients are randomized to:

A: Consolidation with one dose of 90Y Ibritumomab tiuxetan (Zevalin®) 0,4 mCi/Kg

B: Maintenance with 375 mg/m2 of Rituximab every 8 weeks during 24 months

• Phase: Phase 2

Details

• Lead Sponsor: PETHEMA Foundation
• Collaborators: GELCAB; Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
• Treatments: Antibodies, Monoclonal; Rituximab